Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for β-thalassemia major

被引:43
作者
Aker, M
Kapelushnik, J
Pugatsch, T
Naparstek, E
Ben-Neria, S
Yehuda, O
Amar, A
Nagler, A
Slavin, S
Or, R
机构
[1] Hadassah Univ Hosp, Dept Bone Marrow Transplantat, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Dept Pediat, IL-91120 Jerusalem, Israel
[3] Hadassah Univ Hosp, Dept Human Genet, IL-91120 Jerusalem, Israel
[4] Hadassah Univ Hosp, Tissue Typing Unit, IL-91120 Jerusalem, Israel
关键词
beta-thalassemia major; bone marrow transplantation; donor lymphocyte infusion;
D O I
10.1097/00043426-199803000-00011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Donor lymphocyte infusion (DLI) was used to reverse relapse after allogeneic bone marrow transplantation (BMT) in a patient with beta-thalassemia major. Patients and Methods: The patient with unstable mixed chimerism after BMT was treated with graded increments of donor lymphocytes (10(5) T cells/kg to 5x10(7) T cells/kg) to displace residual hematopoietic host cells. Results: DLI resulted in complete donor-derived reconstitution of the hematopoietic compartment. The patient developed mild graft-versus-host disease (GVHD) that could be controlled by steroid treatment. Conclusions: This case report shows that DLI can effectively eradicate host stem cells in mixed chimeras after BMT in nonmalignant hematopoietic diseases.
引用
收藏
页码:145 / 148
页数:4
相关论文
共 18 条
  • [1] BERTHEAS MF, 1991, BLOOD, V78, P3103
  • [2] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
    Collins, RH
    Shpilberg, O
    Drobyski, WR
    Porter, DL
    Giralt, S
    Champlin, R
    Goodman, SA
    Wolff, SN
    Hu, W
    Verfaillie, C
    List, A
    Dalton, W
    Ognoskie, N
    Chetrit, A
    Antin, JH
    Nemunaitis, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 433 - 444
  • [3] DROBYSKI WR, 1992, BONE MARROW TRANSPL, V10, P301
  • [4] DROBYSKI WR, 1993, BLOOD, V82, P2310
  • [5] FRASSONI F, 1990, BONE MARROW TRANSPL, V5, P235
  • [6] Kapelushnik J, 1996, BONE MARROW TRANSPL, V18, P1153
  • [7] ANALYSIS OF BETA-GLOBIN MUTATIONS SHOWS STABLE MIXED CHIMERISM IN PATIENTS WITH THALASSEMIA AFTER BONE-MARROW TRANSPLANTATION
    KAPELUSHNIK, J
    OR, R
    FILON, D
    NAGLER, A
    CIVIDALLI, G
    AKER, M
    NAPARSTEK, E
    SLAVIN, S
    OPPENHEIM, A
    [J]. BLOOD, 1995, 86 (08) : 3241 - 3246
  • [8] DONOR LEUKOCYTE TRANSFUSIONS FOR TREATMENT OF RECURRENT CHRONIC MYELOGENOUS LEUKEMIA IN MARROW TRANSPLANT PATIENTS
    KOLB, HJ
    MITTERMULLER, J
    CLEMM, C
    HOLLER, E
    LEDDEROSE, G
    BREHM, G
    HEIM, M
    WILMANNS, W
    [J]. BLOOD, 1990, 76 (12) : 2462 - 2465
  • [9] MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA RESPONSIVE TO IRON CHELATION-THERAPY
    LUCARELLI, G
    GALIMBERTI, M
    POLCHI, P
    ANGELUCCI, E
    BARONCIANI, D
    GIARDINI, C
    ANDREANI, M
    AGOSTINELLI, F
    ALBERTINI, F
    CLIFT, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (12) : 840 - 844
  • [10] Marrow transplantation for patients with thalassemia: Results in class 3 patients
    Lucarelli, G
    Clift, RA
    Galimberti, M
    Polchi, P
    Angelucci, E
    Baronciani, D
    Giardini, C
    Andreani, M
    Manna, M
    Nesci, S
    Agostinelli, F
    Rapa, S
    Ripalti, M
    Albertini, F
    [J]. BLOOD, 1996, 87 (05) : 2082 - 2088